Sugi Predict

Sugi Predict / Compounds / SCHEMBL23593602

SCHEMBL23593602

SCHEMBL23593602

COCCO[C@@H]1CCN(c2nccc(N)n2)C[C@H]1O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ PDE4D Q08499 1/20 0.35
▸ CD38 P28907 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ PDPK1 O15530 1/20 0.35
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ SUV39H2 Q9H5I1 1/20 0.34
▸ RBP4 P02753 1/20 0.34
▸ TTR P02766 1/20 0.34
▸ EGFR P00533 2/20 0.33
▸ CTSS P25774 1/20 0.33
▸ OGA O60502 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ HRH4 Q9H3N8 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ ACACB O00763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23593521 1.00 KDM1A (0.38) KDM1AKDM4EHPGDPDE4DCD38
SCHEMBL23593536 1.00 KDM1A (0.38) KDM1AKDM4EHPGDPDE4DCD38
SCHEMBL23579286 1.00 KDM1A (0.38) KDM1AKDM4EHPGDPDE4DCD38
SCHEMBL23578759 1.00 KDM1A (0.38) KDM1AKDM4EHPGDPDE4DCD38
SCHEMBL23593515 0.89 ALDH1A1 (0.43) KDM4EHPGDALDH1A1
SCHEMBL23578666 0.87 KDM1A (0.41) KDM1APDE4DSUV39H2RBP4TTR
SCHEMBL23579154 0.87 KDM1A (0.41) KDM1APDE4DSUV39H2RBP4TTR
SCHEMBL23578665 0.87 KDM1A (0.41) KDM1APDE4DSUV39H2RBP4TTR
SCHEMBL23578720 0.87 KDM1A (0.41) KDM1APDE4DSUV39H2RBP4TTR
SCHEMBL23579429 0.87 KDM1A (0.41) KDM1APDE4DSUV39H2RBP4TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289801-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-09-18 — — US disclosed
CN-115135642-B Inhibitors of EGFR mutant forms 缆图药品公司 2025-03-04 — — CN disclosed
US-12172983-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-12-24 — — US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-20230056541-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-02-23 — — US disclosed
US-20230026209-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-26 — — US disclosed
US-20230026209-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-26 — — US disclosed
EP-4081515-A1 INHIBITORS OF MUTANT FORMS OF EGFR Blueprint Medicines Corporation (US) 2022-11-02 — — EP disclosed
CN-115135642-A Inhibitors of mutant forms of EGFR 缆图药品公司 2022-09-30 — — CN disclosed
WO-2021133809-A1 INHIBITORS OF MUTANT FORMS OF EGFR BLUEPRINT MEDICINES CORPORATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056541-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885
US-20230026209-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885
US-11718602-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885
US-12172983-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885
US-20250289801-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 KDM1A 3493/4885KDM4E 3171/4885HPGD 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.